Clinical trial
Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer
NCT00150657 · St. John Providence Health System, Other · Unknown status
Key facts
| NCT number | NCT00150657 |
|---|---|
| Title | Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer |
| Official title | Phase II Trial of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | St. John Providence Health System, Other |
| Collaborators | Genentech, Inc. Industry Eli Lilly and Company |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, carboplatin, gemcitabine |
| Enrollment | 45 |
| Start date | Nov 1, 2004 |
| First posted | Sep 8, 2005 |
| Last update posted | Nov 29, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: